Complicating Factors Surrounding Concurrent Use of Kratom and a Novel 7-hydroxymitragynine Product Among a Participant Enrolled in a Kratom Clinical Trial
Clinicians must obtain detailed self-reports from patients who report any kratom use. As 7-OH products are misleadingly marketed as kratom, and as both long-time kratom consumers and kratom-naive individuals may experiment with these novel products, improved assessment methods are urgently needed in the absence of real-time confirmatory testing.
Authors
- Eric C. Strain (ORCID: https://orcid.org/0000-0001-8482-5461)
- Edward W. Boyer (ORCID: https://orcid.org/0000-0002-5884-0315)
- Christopher R. McCurdy (ORCID: https://orcid.org/0000-0001-8695-2915)
- Raju S. Kanumuri (ORCID: https://orcid.org/0000-0002-6087-6587)
- Kirsten E. Smith (ORCID: https://orcid.org/0000-0002-9278-1830)
- Abhisheak Sharma (ORCID: https://orcid.org/0000-0003-0553-4039)
- R. Lecomte (ORCID: https://orcid.org/0000-0003-2144-9221)
- Rachel Rattenni
Institutions
- Johns Hopkins University (US)
- School of the Art Institute of Chicago (US)
- Johns Hopkins Medicine (US)
- Behavioral Pharma (United States) (US)
- Smiths Detection (United States) (US)
- The Ohio State University (US)
Publication Details
- Journal
- Journal of Addiction Medicine
- Published
- 2025-10-31
- DOI
- https://doi.org/10.1097/adm.0000000000001604
- Citations
- 1
- Primary Topic
- Alkaloids: synthesis and pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.56